Holen Sie sich die Stockscreener-App
6.94
4.52%
0.30
Handel nachbörslich:
6.95
0.010
+0.14%
Schlusskurs vom Vortag:
$6.64
Offen:
$6.72
24-Stunden-Volumen:
2.24M
Relative Volume:
0.83
Marktkapitalisierung:
$1.99B
Einnahmen:
$9.77M
Nettoeinkommen (Verlust:
$-109.00M
KGV:
-19.26
EPS:
-0.3604
Netto-Cashflow:
$-93.83M
1W Leistung:
+10.16%
1M Leistung:
+58.81%
6M Leistung:
+72.21%
1J Leistung:
+182.11%
1-Tages-Spanne:
$6.565
$6.95
1-Wochen-Bereich:
$6.11
$6.95
52-Wochen-Spanne:
$1.845
$6.95
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Firmenname
Taysha Gene Therapies Inc
Sektor
Branche
Telefon
(214) 612-0000
Adresse
3000 PEGASUS PARK DRIVE, DALLAS
Compare TSHA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
6.94 | 1.91B | 9.77M | -109.00M | -93.83M | -0.3604 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Eingeleitet | Raymond James | Strong Buy |
| 2025-07-11 | Eingeleitet | BofA Securities | Buy |
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-04-09 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-01 | Herabstufung | Jefferies | Buy → Hold |
| 2023-01-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | Herabstufung | Goldman | Buy → Neutral |
| 2022-03-09 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-03-01 | Eingeleitet | Wells Fargo | Overweight |
| 2022-02-18 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-12-16 | Eingeleitet | Guggenheim | Buy |
| 2021-07-16 | Eingeleitet | Needham | Buy |
| 2021-06-24 | Eingeleitet | Truist | Buy |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-06-09 | Eingeleitet | Wedbush | Outperform |
| 2021-06-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-05-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-05-11 | Fortgesetzt | Jefferies | Buy |
| 2021-02-24 | Eingeleitet | William Blair | Outperform |
| 2021-01-05 | Eingeleitet | Oppenheimer | Outperform |
| 2020-10-19 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-10-19 | Eingeleitet | Goldman | Buy |
| 2020-10-19 | Eingeleitet | Jefferies | Buy |
| 2020-10-19 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Taysha Gene Therapies Inc Aktie (TSHA) Neueste Nachrichten
Taysha Gene earnings loom with pivotal trial data on horizon By Investing.com - Investing.com Nigeria
Taysha Gene Therapies stock hits 52-week high at 6.77 USD - Investing.com
Taysha Gene Therapies (TSHA) to Release Earnings on Wednesday - MarketBeat
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Five new Taysha hires get 188,000 stock units under Nasdaq rule - Stock Titan
Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6 - Investing News Network
Biotech Taysha pairs its Q1 results with a corporate update on May 6 - Stock Titan
Earnings update from Taysha Gene Therapies expected next week - Traders Union
Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call ... - Caledonian Record
Has Taysha Gene Therapies (TSHA) Run Too Far After A 259% One Year Surge? - Yahoo Finance
Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting - Investing News Network
Taysha to present preclinical data on Rett syndrome gene therapy By Investing.com - Investing.com Canada
Taysha Gene Therapies Reports Preclinical Data Supporting TSHA-102 Gene Therapy for Rett Syndrome at ASGCT Annual Meeting - Quiver Quantitative
Taysha Gene Therapies to Present New Preclinical Data - GlobeNewswire
Taysha Gene Therapies upgraded at Goldman Sachs on advancing Rett syndrome asset - MSN
Taysha Gene Therapies Shares Surge After FDA Grants Breakthrough Therapy Status - MSN
Taysha Gene Therapies stock hits 52-week high at 6.7 USD - Investing.com India
Taysha Gene Therapies, Inc. ($TSHA) CEO and Director 2025 Pay Revealed - Quiver Quantitative
Taysha Gene Therapies (NASDAQ:TSHA) Hits New 12-Month HighShould You Buy? - MarketBeat
Taysha Gene Therapies stock hits 52-week high at 6.7 USD By Investing.com - Investing.com South Africa
Taysha Gene Therapies (TSHA) Stock Price Surges 343.45% From Year Ago Levels - Insider Monkey
Executive pay, board seats and auditor up for TSHA (NASDAQ: TSHA) vote - Stock Titan
This is why Taysha Gene Therapies, Inc. (TSHA) is one of the best healthcare penny stocks to buy - MSN
Taysha Gene Therapies (TSHA) making progress on crucial Rett syndrome treatment - MSN
TSHA Stock Jumps As Canaccord Hikes Price Target - StocksToTrade
TSHA Jumps As Canaccord Hikes Price Target On Trial Progress - timothysykes.com
Taysha Gene Therapies (TSHA) Price Target Raised by JMP on Positive Rett Syndrome Trial Data - MSN
TSHA Jumps As Taysha Gene Therapies Wins Target Hike - StocksToTrade
TSHA Jumps As Taysha Wins Target Hike On Trial Progress - timothysykes.com
Taysha Gene Therapies, Inc. (TSHA) Investor Outlook: Exploring a Potential 94% Upside in the Biotech Arena - DirectorsTalk Interviews
Taysha (TSHA) Stock Treasury Trade (Near Lows) 2026-04-16Breakout Signals - Cổng thông tin điện tử Tỉnh Sơn La
Taysha Gene Therapies Sees Unusually High Options Volume (NASDAQ:TSHA) - MarketBeat
Taysha Gene Therapies stock hits 52-week high at 6.02 USD - Investing.com Australia
Unusually active option classes on open April 16th - TipRanks
Taysha Gene Therapies (NASDAQ:TSHA) Sets New 12-Month HighStill a Buy? - MarketBeat
Needham Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 9%Should You Buy? - MarketBeat
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of "Buy" by Brokerages - MarketBeat
This is Why Taysha Gene Therapies, Inc. (TSHA) is one of the Best Healthcare Penny Stocks to Buy - Insider Monkey
Finanzdaten der Taysha Gene Therapies Inc-Aktie (TSHA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):